Breast cancer is the most common female cancer (1/9 women) and the second highest cause of cancer-related female death. A defining feature of breast cancer cells is uncontrolled proliferation and growth. Our group investigates how breast cells lose control of proliferation and how this alters the DNA of cancer cells.  We use a combination of traditional laboratory methods, genomics and bioinformatics to address this question. We have made significant findings on potential biomarkers for cancer, especially drug-resistant disease, and how to tailor hormone and chemotherapy treatments for breast cancer cells.

Our research focus is:

  1. How cyclin E2, a protein that drives proliferation, can alter how cells respond to DNA damage to make cells more unstable;
  2. The way that proliferation pathways in the cell intersect with other processes (growth, DNA transcription) and can be disrupted in cancer;
  3. Genomic instability in endocrine resistant breast cancer.

Selected Publications

Rogers, S., Gloss, B., Lee, C.S., Sergio, C.M., Dinger, M.E., Musgrove, E.A., Burgess A., Caldon, C.E. (2015). Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Division, 10(1), 1.

Caldon C.E., C.M. Sergio, A. Burgess, A.J. Deans, R.L. Sutherland, E.A. Musgrove. Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle. 2013; 12(4):606-17.

Caldon C.E., C.M. Sergio, R.L. Sutherland, E.A. Musgrove. Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells. Cell Cycle. 2013; 12(4):596-605.

Caldon, C. E., C. M. Sergio, J. Kang, A. Muthukaruppan, M. N. Boersma, A. Stone, J. Barraclough, C. S. Lee, M. A. Black, L. D. Miller, J. M. Gee, R. I. Nicholson, R. L. Sutherland, C. G. Print and E. A. Musgrove. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Molecular Cancer Therapeutics 2012; 11(7):1488-1499.

Musgrove, E. A., C. E. Caldon, J. Barraclough, A. Stone and R. L. Sutherland. Cyclin D as a therapeutic target in cancer. Nature Reviews Cancer 2011; 11(8): 558-572.

Caldon, C. E., R. L. Sutherland and E. A. Musgrove. Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer. Cell Cycle 2010; 9: 10.

Caldon, C. E. and E. A. Musgrove. Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Division 2010; 5(2).

Caldon, C. E., C. M. Sergio, J. Schutte, M. N. Boersma, R. L. Sutherland, J. S. Carroll and E. A. Musgrove. Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Molecular and Cellular Biology 2009; 29(17):4623-4639.

Caldon, C. E., A. Swarbrick, C. S. Lee, R. L. Sutherland and E. A. Musgrove. The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Research 2008; 68(8):3026-3036.

Caldon, C. E., C. S. Lee, R. L. Sutherland and E. A. Musgrove. Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. Oncogene 2008; 27(1):126-138.

Caldon, C. E., R. J. Daly, R. L. Sutherland and E. A. Musgrove. Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry 2006; 97(2):261-274.


More Garvan Publications

Staff in the Group

Christine Lee

Senior Research Assistant

Sarah Alexandrou

Honours Student

In the News

Group Leader

Dr Liz Caldon


Diseases We Research
Breast Cancer

Loading jobs...